Baudax Bio
Pharmaceuticals, 490 Lapp Rd, Malvern, Pennsylvania, 19355, United States, 51-200 Employees
Phone Number: 48********
Who is BAUDAX BIO
Baudax Bio is a revenue-generating, specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings. The Company has multiple non-op...
Read More
-
Headquarters: 490 Lapp Rd, Malvern, Pennsylvania, 19355, United States
-
Date Founded: 2019
-
Employees: 51-200
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from BAUDAX BIO
Baudax Bio Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Baudax Bio
Answer: Baudax Bio's headquarters are located at 490 Lapp Rd, Malvern, Pennsylvania, 19355, United States
Answer: Baudax Bio's phone number is 48********
Answer: Baudax Bio's official website is https://baudaxbio.com
Answer: Baudax Bio's revenue is $1 Million to $5 Million
Answer: Baudax Bio's SIC: 2834
Answer: Baudax Bio has 51-200 employees
Answer: Baudax Bio is in Pharmaceuticals
Answer: Baudax Bio contact info: Phone number: 48******** Website: https://baudaxbio.com
Answer: Baudax Bio is a revenue-generating, specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings. The Company has multiple non-opioid therapeutics in clinical development for the treatment of pain conditions and is currently promoting their lead product, ANJESOTM, indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Our pipeline also includes other early-stage product candidates, including two novel neuromuscular blocker agents (NMBs) and a related proprietary chemical reversal agent, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine, a selective alpha-2 adrenergic agonist that has demonstrated sedative, analgesic and anxiolytic properties. We believe we can create value for patients and shareholders through our robust pipeline of product candidates. In addition, we continue to evaluate acquisition and licensing opportunities which align with our core acute care focus.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month